Compare CVS Health Corp (CVS) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Prudential PLC — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while Prudential PLC trades at $24.03 (market cap $28.76B). The key difference: CVS Health Corp is far larger — about 3.9× Prudential PLC's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Prudential PLC for 119 Days on average.
| CVS | PUK | |
|---|---|---|
Market Cap | $112.49B | $28.76B |
Volume | 8,467,392 | 1,285,651 |
Sector | Health | Financials |
52-Week High | $110.60 | $33.61 |
52-Week Low | $70.08 | $23.54 |
Typical Hold Time | 83 Days | 119 Days |
Enterprise Value | $174.83B | $28.30B |
Dividend Yield | 3.02% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
PUK trades at $23.88, down 2.93% over 24 hours, amid a bearish technical signal. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent earnings show mixed quarterly results, with two beats and two misses versus expectations. Analyst consensus is moderately bullish, with 50% buy ratings. The firm is executing a strategic overhaul, including a $3B capital rotation plan and exiting certain markets to sharpen focus.
The outlook is cautiously optimistic given solid profitability and strategic initiatives, but near-term headwinds include earnings volatility and bearish technical indicators. Risks involve execution of the restructuring and macroeconomic pressures. The stock presents a value opportunity with a low P/E of 8.28, though investors should weigh the mixed earnings record against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
